A key element of the BioScience Managers model is an international network of industry experts, which we call on, on an as-needed basis to inform our investment decisions and ongoing portfolio management.
Industry Advisors come from over 10 different countries and span across a broad cross section of specialist skills such as:- scientific, medical device, drug (small molecule and protein) development, CMC (chemistry, manufacturing & control), toxicology, clinical trials, regulatory, intellectual property, finance, pharmaceuticals, and law.
Some of our industry advisors include:
Dr. Hunter is currently the President and CEO of Cardiome Pharm Corporation, a commercial-stage NASDAQ and TSE listed healthcare company with an approved drug treatment (BRINAVESS™) for atrial fibrillation.
Prior to Cardiome, Dr. Hunter co-founded Angiotech Pharmaceuticals in 1992 and assumed the position of Chief Executive Officer in 1997 when Angiotech was a venture-stage, private, pre-clinical company with less than 50 employees. He led Angiotech through 3 rounds of private equity financing, the Company’s IPO and listing on the Toronto Stock Exchange and NASDAQ, over $1B in equity and debt financings, a debt restructuring and 8 separate corporate acquisitions. During that time, Angiotech grew to become a profitable, diversified, healthcare company with over 1,400 employees, several thousand commercially available products, 12 facilities in 5 countries and worldwide annual revenues exceeding $250M.
Dr. Hunter has over 200 patents and patent applications to his name and products in which he was an inventor or co-inventor include the TAXUS® Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug-Eluting Stent, the Quill barbed wound closure device and the 5-FU Anti-Infective Catheter; combined these products have been used in over 6 million patients worldwide and recorded revenues of over $12 billion.
Dr. Hunter currently serves a director of Cardiome, Zalicus Inc (NASDAQ: ZLCS) and Rex Bionics plc and has served previously on the boards of Aspreva Pharmaceuticals, Anormed Pharmaceuticals, Active Pass Pharmaceuticals, Neuromed Pharmaceuticals and Angiotech Pharmaceuticals.
Dr Doug Wilson is the former Senior Vice President for Medicine and Regulatory Affairs for Boehringer Ingelheim, USA, overseeing all clinical research programmes and interactions with FDA. During this period he was part of a lead team that saw 10 drugs complete successful NDAs and go onto the US market. He then became responsible for the same functions world-wide at the Company’s head office in Ingelheim, Germany. He was deputy chair for some years of the company’s International Medical Committee which oversaw all drugs in development globally and would assess up to 50 or more projects on a regular basis. He chaired the company’s International Labelling Committee which oversaw all drug labelling and safety for drugs around the world and was a core member of the company’s International Steering Committee which supervised the company’s major financial investments globally.
Nora studied modern biology (microbiology, biochemistry) and economics in Basel and holds a masters degree in Microbiology and a PhD in Biochemistry in the field of drug-induced autoimmune diseases from the University of Basel.
She was partner at Bellevue Group, Zug, Switzerland and part of the BB Biotech management team managing up to CHF 4B in public and private biotech investments. In 2000 she conceived and founded Adamant Biomedical Investments AG in Basel, Switzerland.
Among several other awards, Nora was voted finalist in the Ernst &Young Entrepreneur of the Year Award in Switzerland. She was responsible for the establishment of a subsidiary of Adamant, Adamant Ventures Ltd., in Edinburgh, UK.
Towards the end of 2008, Nora left Adamant to found Cederberg Advisors.
Nora is a citizen of Germany and Switzerland.